Eye fluid study for wet AMD treatment response
Treatments studied
Part of Eyes & vision clinical trials.
This study looks at eye fluid from people with untreated wet AMD to find out why some don't respond well to standard injections. The goal is to improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older
- You have been diagnosed with wet AMD that has not been treated before
- You have certain vision loss levels (between 20/32 and 20/320 on an eye chart)
- You are willing to have eye exams and provide a fluid sample during a scheduled procedure
- If female, you must not be able to become pregnant or have a negative pregnancy test and agree to birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
This study tests whether a new eye drop medication (SCAI-005) can help people with wet age-related macular degeneration (a serious eye condition affecting central vision in older adults) who have already responded well to regular eye injections. The goal is to see if eye drops might work as an alternative treatment.
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
This study observes how a drug called faricimab works in treating wet AMD (a condition affecting central vision in older adults). You would receive four initial injections into your eye, then additional injections as needed based on your response.
This trial tests an investigational drug called SCT520FF for people with wet age-related macular degeneration (nAMD). It aims to find the safest dose and check if it can improve vision. You may be eligible if you have active new blood vessels in your eye from nAMD and have not had certain other eye problems.
This study looks at how quickly fluid in the retina clears after starting treatment with a higher dose of Eylea (aflibercept 8mg) for wet age-related macular degeneration (AMD). It aims to understand if early fluid changes can predict long-term outcomes.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.